Navigation Links
AAOMS Updates BRONJ Position Paper
Date:1/22/2009

ROSEMONT, Ill., Jan. 22 /PRNewswire-USNewswire/ -- The American Association of Oral and Maxillofacial Surgeons has revised its 2006 landmark position paper on Bisphosphonate-Related Osteonecrosis of the Jaw to reflect the most current research and thought on this condition. BRONJ appears as a non-healing exposed bone in the maxillofacial region and may affect patients undergoing intravenous cancer-related bisphosphonate therapy or more rarely, patients treated with oral or IV bisphosphonates for osteoporosis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050125/CGTU021LOGO)

Written by the members of the distinguished AAOMS Task Force on BRONJ who prepared the original paper, the 2009 BRONJ Position Paper updates the staging and management strategies for BRONJ, and highlights the status of basic science research relating to this condition.

The 2009 Position Paper retains the case definition of BRONJ:

1. The patient is or has been treated with a bisphosphonate.

2. Exposed bone has been present in the maxillofacial region for more than eight weeks; and

3. There is no history of radiation therapy to the jaws.

While there is strong evidence supporting an association between IV bisphosphonate therapy for cancer-related conditions and BRONJ, the 2009 BRONJ Position Paper stresses that the relationship between oral or IV bisphosphonates for treating osteoporosis and BRONJ is more difficult to establish.

Specifically, the 2009 BRONJ Position Paper observes that the risk of developing BRONJ is linked to:

1. The potency the bisphosphonate used in therapy; and

2. The length of exposure to bisphosphonates.

Other factors that may increase the risk of developing BRONJ include:

  • A history of inflammatory dental disease, such as periodontal disease and dental abscesses;
  • Increased age;
  • Other systemic factors or conditions, such as renal dialysis, low hemoglobin, obesity and diabetes; and
  • In some cases, there may be a genetic predisposition to developing BRONJ.

The 2009 BRONJ Position Paper offers some strategies for preventing BRONJ in cancer patients treated with IV bisphosphonates.

  • Prior to initiation of cancer-related IV bisphosphonate treatment, patients should have a thorough dental examination and complete the necessary procedures to achieve optimal periodontal health.
  • Given the long-term biologic activity of IV bisphosphonates noted in the literature, the 2009 Position Paper suggests that alternative dosing regimens that reduce bisphosphonate exposure may be effective in decreasing the risk for BRONJ.

Changes to the staging system include the addition of Stage 0, which includes patients exposed to bisphosphonates and who present with non-specific symptoms, or clinical and radiographic abnormalities.

BRONJ is painful and difficult to treat. While osteonecrosis of the jaw has been recognized by dental and medical practitioners for many years, the identification of bisphosphonates as a contributory factor to the condition was first reported by oral and maxillofacial surgeons about five years ago when they noticed an increase in the number of patients exhibiting the signs of ONJ. A review of these cases indicated that bisphosphonate therapy was a common thread.

In 2006, the American Association of Oral and Maxillofacial Surgeons appointed the Task Force on BRONJ to review the existing literature and prepare a position paper that synthesized the findings for the dental and medical communities.

In late 2008, the Task Force on BRONJ was reconstituted to review the research conducted in the intervening two years. The 2009 BRONJ Position Paper is the result of their efforts.

The complete 2009 BRONJ Position Paper is available at aaoms.org

(http://www.aaoms.org/docs/position_papers/bronj_update.pdf).

Saving Faces, Changing Lives -- The American Association of Oral and Maxillofacial Surgeons (AAOMS), the professional organization representing more than 8,500 oral and maxillofacial surgeons in the United States, supports its fellows' and members' ability to practice their specialty through education, research and advocacy. AAOMS fellows and members comply with rigorous continuing education requirements and submit to periodic office examinations, ensuring the public that all office procedures and personnel meet stringent national standards.


'/>"/>
SOURCE American Association of Oral & Maxillofacial Surgeons
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
2. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
3. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
4. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
5. Genmab Announces Updates on Phase III Cancer Studies
6. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
7. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
8. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. BioCryst Updates Peramivir Clinical Development Plan
11. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
Breaking Medicine News(10 mins):